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Available online 28 June 2018Background: Epicardial adipose tissue (EAT) thickness and pro-inﬂammatory status has been shown to be
associated with several cardiac diseases, including aortic stenosis (AS). Thus, cardiac visceral fat could represent
a potential new target for drugs. In the present studyweevaluate the effect of statin therapy on EAT accumulation
and inﬂammation.
Methods: Echocardiographic EAT thickness was assessed in 193 AS patients taking (n.87) and not taking (n.106)
statins, undergoing cardiac surgery. To explore the association between statin therapy and EAT inﬂammation,
EAT biopsies were obtained for cytokines immunoassay determination in EAT secretomes. An in vitro study
was also conducted and the modulation of EAT and subcutaneous adipose tissue (SCAT) secretomes by
atorvastatin was assessed in paired biopsies.
Results: Statin therapy was signiﬁcantly associated with lower EAT thickness (p b 0.0001) and with lower levels
of EAT-secreted inﬂammatory mediators (p b 0.0001). Of note, there was a signiﬁcant correlation between EAT
thickness and its pro-inﬂammatory status. In vitro, atorvastatin showed a direct anti-inﬂammatory effect on
EAT which was signiﬁcantly higher compared to the SCAT response to statin incubation (p b 0.0001).
Conclusions: The present study indicates a robust association between statin therapy and reduced EAT
accumulation in patients with AS. The present data also suggest a direct relationship between EAT thickness
and its inﬂammatory status, both modulated by statin therapy. The in vitro results support the hypothesis of a
direct action of statins on EAT secretory proﬁle. Overall our data suggest EAT as a potential new therapeutic target
for statin therapy.





Statin therapy has an established role on primary and secondary
prevention of cardiovascular diseases [1–5]. The beneﬁcial effects
of this class of drugs on cardiovascular outcomes go beyond the lipid
levels control and accumulating evidence support the relevance of
statin-related pleiotropic activities. Beside the inhibition of HMG-CoAal Medical Sciences, University
eliability and freedom from biasreductase and mevalonate pathway, statins may affect a variety of pro-
cesses such as cell signalling, cell differentiation and proliferation [6].
At this regard, it has been emphaticized the role of statins in attenuating
inﬂammation, a well-recognized substrate of the atherosclerotic
process [7–9]. Few data also suggest a potential anti-inﬂammatory
effect of statins on visceral fat depots, such as omental and thymus
adipose tissue [10, 11], however nodata are available on cardiac visceral
fat. Epicardial adipose tissue (EAT), the visceral fat of the heart, repre-
sents a source of several adipocytokines and other bioactive molecules
[12, 13]. Because of its proximity to the myocardium and absence of
fascial boundaries, EAT directly inﬂuences myocardial homeostasis
through vasocrine and paracrine mechanisms. Increased secretion of
EAT inﬂammatory mediators are associated to pathological cardiac
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[12, 14]. The potential mechanistic involvement of EAT in the develop-
ment and progression of cardiac diseases gave raised to hypothesize
that the cardiac visceral fat could represent a new potential therapeutic
target other than a risk factor for cardiac pathologies. However, until
now, deﬁnitive evidence of the efﬁcacy of speciﬁc drug therapies in
modifying EAT pathologic phenotype are not still available. To this
aim, in the present study, we want to explore, in vivo and in vitro,
whether statin therapy could regulate EAT accumulation and pro-
inﬂammatory activity in patients with severe calciﬁc aortic stenosis
(AS), whose associationwith increased EAT thickness and inﬂammatory
status has been recently reported by our group [14].
2. Methods
2.1. Study population
From April 2014 to December 2017, we enrolled 193 patients with isolated severe
calciﬁc aortic stenosis admitted for clinical evaluation prior aortic valve replacement to
two cardiac surgery centers (University of Naples Federico II, Italy, and San Michele
Hospital, Maddaloni, CE, Italy). Of these, 87 patients (45.1%) were on statin therapy for a
duration ranged from 3 to 72 months. Since the low proportion of non-statin users in
patients with coronary artery disease (CAD), we excluded from the study subjects
with previous diagnosis of CAD and with signiﬁcant CAD at the pre-operative coronary
angiography. Furthermore, in order to minimize potential confounding factors, we also
excluded patients with chronic inﬂammatory diseases and cancer since the association
of these pathologic conditions with visceral fat inﬂammation. From all patients we
collected demographic and clinical data. The study protocol conforms to the ethical
guidelines of the 1975 Declaration of Helsinki. All the study procedures received approval
by our institution's human research committee (Protocol n. 173/13). All patients provided
written informed consent before their inclusion into the study.
2.2. Echocardiography
All patients underwent complete echocardiographic study (GE vivid E9) and the diag-
nosis of severe aortic stenosis was conﬁrmed in accordance to the recently published
criteria [15]. The maximum EAT thickness was measured in systole, from the parasternal
long axis view that visualizes EAT tissue between the right ventricle and the ascending
aorta. Measurements of EAT thickness were performed ofﬂine by two independent,
blinded, echocardiographers. The average value from three cardiac cycles was used for
the statistical analysis.
2.3. Tissues collection
Throughout the entire enrollment period, we collected EAT biopsies from a subgroup
of 31 patients undergoing cardiac surgery for valve replacement. EAT biopsy samples
(average 0.1 to 0.5 g) were taken near the proximal right coronary artery before the
initiation of cardiopulmonary bypass. For the in vitro study also subcutaneous adipose
(SCAT) (average 0.1 to 0.5 g) samples were obtained from the chest.
2.4. Cytokine and growth factor assay
From EAT biopsies, secretomes were obtained as follows: tissues were weighted,
cut into small pieces, and transferred into a 12-well plate. According to tissue weight,
serum-free DMEM (1 mL medium/0.1 g tissue) was added to the well and incubated
at 37 °C in a CO2 incubator. After 24 h, medium was collected and centrifuged at
14,000g to remove debris and analysed for cytokines and growth factors content,
as described below.
EAT conditioned media was screened for the concentration of Interleukin (IL)-1β,
IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, basic Fibroblast
Growth Factor (FGF), Eotaxin, Granulocyte-Colony Stimulating Factor (G-CSF),
Granulocyte–Macrophage Colony Stimulating Factor (GM-CSF), Interferon (IFN)-γ, Inter-
feron gamma-Induced Protein (IP)-10, Monocyte Chemoattractant Protein (MCP)-1,
Macrophage Inﬂammatory Protein 1-alpha/beta (MIP-1α, MIP-1β), Platelet-Derived
Growth Factor (PDGF), Regulated on Activation Normal T-cell Expressed and Secreted
RANTES/CCL5, Tumor Necrosis Factor (TNF)-α, and Vascular Endothelial Growth Factor
(VEGF), using the Bio-Plex multiplex Human Cytokine and Growth factor kits (Bio-Rad)
according to the manufacturer's protocol.
2.5. In vitro study
To verify whether statins might directly affect EAT inﬂammatory proﬁle, we in vitro
treated with atorvastatin EAT and SCAT specimens obtained from patients not taking
statins. To reduce any confounding factor, we used paired biopsies. In particular, each
biopsy was cut in two equal pieces, transferred into culture plates and treated or not
with 2 μM Atorvastatin at 37 °C in a CO2 incubator. After 24 h, conditioned media werecollected, centrifuged at 14,000g to remove debris and analysed for cytokines and growth
factors content, as described above.
2.6. Materials
Mediawere from Lonza (Lonza Group Ltd., Basel, Switzerland). Atorvastatinwas from
Sigma-Aldrich (St. Louis, MO, USA).
2.7. Statistical analysis
In order to assess the association between statin therapy and EAT thickness a multi-
variable regression model was tested between the echocardiographic EAT thickness, as
dependent variable, whereas statin use, acetyl salicylic acid use (ASA), age, male sex,
body mass index (BMI), hypertension, diabetes, dyslipidaemia and smoking habit were
included as independent variables. Statin therapy was tested as effect modiﬁer while the
others variables were tested as possible confounders and were selected from factors
potentially associated with EAT thickness. The model building procedure was centred on
the multivariable fractional polynomial (MFP) algorithm [16] that allows both backward
stepwise variable selection and assessment of the functional form (linearity/non linearity)
on the continuous variables. The possible presence of multicollinearity between the inde-
pendent variables tested in the model was checked by measuring the variance inﬂation
factor (VIF). The relevance of the factors included in the ﬁnal model was assessed by
each partial contribution to the global explained variance (R2) that was accomplished
by the Shapley-Owen decomposition algorithm [17]. The stability of the results obtained
in the ﬁnal model was assessed by measuring the internal validity with nonparametric
bootstrap sampling [18]. Brieﬂy, given the parameters of the ﬁnal model obtained with
the mentioned model-building procedure, the stability of each factor tested in the
model was measured by the frequency that this factor is selected as ‘signiﬁcant’ in a
large (1000) number of bootstrap replications of the dataset (BIF).
In order to verify in vivo the relationship between EAT cytokine levels and statin
therapy, a two-way ANOVA fullmodelwith interactionwas used on logarithmof cytokine
concentration with statin use and cytokine type as main effects. A two-way ANOVA full
model with cytokine type and specimen site (EAT or SCAT) was used to investigate




Table 1 illustrates demographic and clinical characteristics of the
overall study population. The mean age was 72.2 ± 10.5 years and
43% of patients were males. As regard to common atherosclerotic risk
factors, 75.6% of patients were hypertensives, 29.5% were diabetics,
32.1% were smokers and 53.9% were dyslipidemics. Seventy percent of
patients assumed ACE-inhibitors/sartans, 24.9% calcium-channel
blockers, 64.8% beta-blockers, and 60% aspirin. Use of statins was
reported in 45% of patients. Eighty-twopercent of statin treatedpatients
were on atorvastatin (40 mg once daily, mean duration = 24 ±
17 months), 11% on rosuvastatin (20 mg once daily, mean duration =
19 ± 12 months), and 7% on pravastatin (20 mg once daily, mean
duration= 31± 18months). At echocardiography, all patients fulﬁlled
criteria of severe AS [15], mean left ventricular ejection fraction (LVEF)
was 66.0 ± 10.8%, thus indicating a globally preserved LV systolic
function. Mean EAT thickness was 11.3 ± 3.2 mm. Intra and inter-
observer reproducibility for echocardiographic EAT thickness assess-
ment was excellent (0.964 and 0.953, respectively).
3.2. Multivariable determinants of EAT thickness
Table 2 reports the multivariable determinants of EAT thickness.
Multicollinearity check gave a mean VIF equal to 1.2 with an observed
maximum of 1.3, well below the critical values of 4 [19, 20], thus
documenting absence of multicollinearity bias. Statin therapy and
dyslipidaemia were the only two factors retained signiﬁcant in the
ﬁnal model. A 16% fraction of the total variance observed in the EAT
thickness was explained by the model. Notably, N96% of this was
accounted by the statin therapy while b4% was attributable to the
presence of dyslipidaemia. Both statin use and dyslipidaemia showed
a linear functional form in all bootstrap resamples. Interestingly, statin
therapy showed an excellent signiﬁcance stability (BIF = 100%) when
compared to dyslipidaemia that resulted signiﬁcant only in the 55% of
Table 1
Demographic and clinical characteristics of study population.
Age, mean ± SD 72.2 ± 10.5
Gender, male % (n) 43.0% (83)
BMI, mean ± SD 28.4 ± 5.4
Hypertension, % (n) 75.6% (146)
Diabetes, % (n) 29.5% (57)
Smokers, % (n) 32.1% (62)
Dyslipidemia, % (n) 53.9% (104)
ACE-I/ARB % (n) 66.8% (129)
CCBs, % (n) 24.9% (48)
BBs, % (n) 64.8% (125)
Statins, % (n) 45.1% (87)
ASA, % (n) 59.6% (115)
LVEF, % 66.0 ± 10.8
EAT thickness, mm 11.3 ± 3.2
BMI=bodymass index;ACE-I=ACE inhibitors; ARBs=angiotensin
receptor blockers; CCBs = calcium channel blockers; BBs =
beta-blockers; ASA = Acetylsalicylic Acid; LVEF = left ventricular
ejection fraction; EAT = epicardial adipose tissue.
Fig. 1. EAT cytokine secretome concentrations ± mean square error in patients taking or
not statin therapy. EAT; epicardial adipose tissue.
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effects of statin and ASA use on EAT thickness, no signiﬁcant interaction
was found between these two variables in the model.
3.3. In vivo effects of statin therapy on EAT inﬂammatory proﬁle
We explored the relationship between statin therapy and the
concentration of cytokines in EAT secretome. The two-way ANOVA
(Table 3, Supplemental material) showed a signiﬁcant association
between statin therapy and EAT cytokines concentrations. This effect
is also visually appreciable in the Fig. 1 showing the cytokines that
were particularly affected by statin therapy. The not signiﬁcant
cytokine/statin interaction leads to conclude that such association is
not modulated by cytokine types. Probably, a small difference between
cytokine types compared to data variability hides the interaction effect.
Of interest, cytokine concentrations were signiﬁcantly (p ≤ 0.001) and
directly correlated with EAT thickness at a two-way ANOVA that took
into account cytokine type (Table 4, Supplemental material). Moreover,
even in this subgroup of patients, the signiﬁcant, direct relationship
between EAT thickness and statin use was conﬁrmed (p ≤ 0.001),
thus supporting the hypothesis of a close interaction between EAT
accumulation and its exalted inﬂammatory proﬁle.
3.4. In vitro effects of atorvastatin on EAT inﬂammatory proﬁle
To conﬁrm the statin related effect on EAT and minimize any
possible confounding effect, we planned an in vitro experiment
with paired biopsies matching the effect of statin on EAT and SCAT.
To compare the effect of statin stimulation, the results of the 27 cyto-
kines analysis were expressed as the concentration ratios between the
treated/not treated specimen halves. The two-way ANOVA analysisTable 2
Multivariable regression analysis of variables associated with EAT thickness.
Global R2 = 0.16
Coeff. p Perce
of glo
Age 0.0 0.17 NA
Gender (male) −0.7 0.13 NA
BMI 0.1 0.09 NA
Hypertension 0.4 0.4 NA
Diabetes −0.1 0.84 NA
Dyslipidemia 1.0 0.04 3.7%
Smoking habit 0.07 0.87 NA
Statin therapy −2.8 ≤0.0001 96.3%
ASA 0.33 0.48 NA
ASA = acetylsalicylic acid; BMI = body mass index; EAT = epicardial adipose tissue; NA not a(Table 5, supplemental material) showed a signiﬁcant lower ratio in
the EAT specimen, denoting a greater reduction of cytokines concentra-
tion in the EAT tissue after statin incubation when compared to SCAT
incubation response. The signiﬁcant interaction with cytokine type
indicates that cytokine type modulates this effect and gives rise to a
differentiated response for each cytokine, as evidenced in Fig. 2 were
each cytokine ratio was ordered by the response magnitude.
4. Discussion
In a model of atherosclerotic cardiac disease, the calciﬁc AS, whose
association with increased EAT thickness and inﬂammatory status has
been recently reported [14], we explored, in vivo and in vitro, whether
statin therapymight affect EAT accumulation and inﬂammatory proﬁle.
Major ﬁndings of the present study are: 1) statin therapy is signiﬁcantly
associated to a reduced EAT thickness; 2) the association between statin
therapy and reduction of EAT accumulation is paralleled by an attenua-
tion of EAT inﬂammatory proﬁle; 3) as indicated by the vitro studies,
statin have a direct and selective anti-inﬂammatory effect on EAT.
EAT represents a marker of visceral adiposity and its mass is
increased in several metabolic and cardiovascular diseases, such as
metabolic syndrome, insulin resistance and CAD [21–24]. We have pre-
viously reported [14] that EAT thickness is also increased in patients
with AS and represents a relevant source of inﬂammatory cytokines.
In the present study, in order to explore a potential effect of statins on
EAT pro-inﬂammatory proﬁle, we selected a population of patients
with AS, since, in this clinical setting, statin prescription is not manda-
tory following the recommendations of the current guidelines. This
















Fig. 2. In vitro atorvastatin/control ratios of cytokine secretome concentrations in EAT and
SCAT. EAT; epicardial adipose tissue. SCAT; Subcutaneous adipose tissue.
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therapy was a signiﬁcant predictor of EAT thickness, when added to a
clinical model including age, male sex, BMI, hypertension, diabetes,
dyslipidaemia and smoking habit. Of note, the linear functional form
in all bootstrap resamples and the excellent signiﬁcance stability of
this association strengthened the result of the performed analysis. This
ﬁnding is in line with previous evidence obtained in other settings
[25–27] indicating a statin-related reduction of EAT in patients with
CAD, atrial ﬁbrillation, and dyslipidaemia. Interestingly, our results
suggest, for the ﬁrst time, that the association of statin therapy with a
lower EAT thickness is paralleled by an attenuation of the inﬂammatory
proﬁle of the cardiac visceral fat. In particular, we observed a signiﬁcant
association between statin therapy, EAT thickness and levels of
cytokines secreted from this tissue.
A direct evidence of themodulating activity of statin therapy on EAT
pro-inﬂammatory proﬁle was provided by the in vitro results of the
present study. Analysing EAT paired biopsies obtained from AS patients
not assuming statins, atorvastatin showed a signiﬁcant effect in reduc-
ing cytokine concentrations in cardiac visceral fat. These observations
are corroborated by previous in vitro animal studies describing the
anti-inﬂammatory effect of statins on visceral adipose tissue. In this
regard, statins have been shown to suppress macrophage-mediated
inﬂammatory response of the adipocytes extracted from the visceral
fat of obesemice [28]. Overall, these evidence support the role of statins
in regulating the secretory properties of visceral fat and our study now
extends these previous observations to the cardiac human visceral fat.
Noteworthy, our data also indicated that the anti-inﬂammatory effect
of atorvastatin was signiﬁcantly greater in EAT than in SCAT. The
different responses of these two adipose tissues to statin stimulation
represent another evidence that EAT and SCAT not only differ in terms
of morphologic characteristics but also show a different secretory
phenotype. This confers a unique role to EAT in cardiac diseases and
strengthens the concept that cardiac visceral fat is a more metabolically
active tissue than SCAT [11, 14].
A signiﬁcant interaction with cytokine type was revealed by in vitro
experiments of the present study, indicating that cytokine type modu-
lated the response of EAT to atorvastatin. Of interest, this effect seemed
to be mainly driven by IL-6 and IL-8 (Fig. 2), two of the most studied
cytokines in the atherosclerotic process and already associated to the
statin related beneﬁt in experiments conducted on coronary artery
endothelial cells [29, 30]. A similar trend for statin induced IL-6 and
Il-8 reduction, although not statistically signiﬁcant, was found in vivo.
In conclusion, the present study suggests, for the ﬁrst time, an asso-
ciation between statin therapy, EAT thickness and inﬂammatory proﬁle
in patients with AS. In particular, our results indicate that the statinrelated EAT anti-inﬂammatory effect is the result of a direct action on
cardiac visceral fat and is paralleled by a reduction of EAT thickness at
echocardiography. Although our results may give only preliminary in-
formation on statin doses in AS patients, they encourage the realization
of future studies in this ﬁeld that could be helpful to cardiologists to
deﬁne the optimal doses for the treatment of this patients' population.
Finally, since the relationship between EAT thickness and its secretory
proﬁle, other studies should be planned to evaluate if the echocardio-
graphic evaluation of this cardiac adipose deposit could be utilized as
a surrogate marker of the EAT inﬂammatory status in the clinical prac-
tice and whether the statin-related effect on EAT morphological and
functional remodelling could impact on cardiovascular outcomes.
4.1. Study limitations
This was not a longitudinal study, thus, EAT thickness was not
monitored over time before and during statin therapy. However, in
the present study, we needed to enroll patients with advanced aortic
valve disease. All these patients underwent urgent surgical valve
replacement, thus, giving us the opportunity, in a subgroup of them,
to obtain human EAT tissues for in vivo and in vitro experiments.
Future longitudinal studies, conducted on patients with less advanced
AS, are necessary to follow over time the effect of statin therapy on
EAT thickness.
Since the limited availability of human EAT biopsies, the in vitro
section of the present study evaluated the anti-inﬂammatory effects of
a single statin, atorvastatin, thus avoiding us to extend this observation
to other components of this class of drugs. The choice of atorvastatin
was based on the following reasons: 1) the majority of our patients on
statin regimen were on atorvastatin therapy; 2) previous evidence
have already demonstrated an anti-inﬂammatory effect of atorvastatin
on human adipocytes in other settings [13]. Further studies are needed
to explore whether the observed anti-inﬂammatory effects on EAT
might be obtained with other molecules.
Both in vivo and in vitro studies on EAT secretome have been con-
ducted on the whole tissue. Since the cell type mix in EAT, we cannot
say whether the anti-inﬂammatory effect of statin has to be mainly
referred to a direct activity on the adipocyte secretory properties or on
the inﬂammatory cell lines expressed in this tissue.
It would have been more reliable once a positive control was
included in the in vitro study but the limited amount of EAT tissues
was not sufﬁcient to perform this kind of experiments.
An apparent limitation of this study is represented by the lack of
data regarding systemic inﬂammation in our AS population. In this
regard, our group and other have already demonstrated that local in-
ﬂammation assessed at EAT level is independent from the systemic
levels of the explored cytokines [12, 14]. As regard the systemic effect
of statin therapy in the AS population, previous studies have demon-
strated that statins induce reduction of systemic inﬂammation, assessed
by circulating C-reactive protein (CRP) levels [31]. However, CRP is
predominantly produced in the liver, thus being poor affected by local-
ized inﬂammation phenomena, such as that explored in the present
study [32].
Echocardiographic EAT measurement has several advantages,
such as low cost and easy availability, but it also has some limitations
because it might not fully reﬂect the variability of fat thickness or
total EAT volume as assessed with cardiac magnetic resonance.
However, the EAT echocardiographic evaluation has been reported
to correlate with magnetic resonance measurements [33] and
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Supplementary data to this article can be found online at https://doi.
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